Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer

American Journal of Surgical Pathology

Volumn 26, Issue 4, 2002, Pages 431-439

  Sebo, Thomas J ^a   Cheville, John C ^a   Riehle, Darren L ^a   Lohse, Christine M ^a   Pankratz, V Shane ^a   Myers, Robert P ^a   Blute, Michael L ^a   Zincke, Horst ^a  

^a MAYO CLINIC   (United States)

Author keywords

Biopsy; Cancer progression; Carcinoma; DNA ploidy; Gleason score; MIB 1; Neoplasm; Prostate

Indexed keywords

DNA; MONOCLONAL ANTIBODY KI 67; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER RECURRENCE; CANCER STAGING; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERINEURIUM; PLOIDY; PREDICTION; PREOPERATIVE PERIOD; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; SCORING SYSTEM;

ADULT; AGED; ANTIGENS, NUCLEAR; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NUCLEAR PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0036211091     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200204000-00004     Document Type: Article

References (53)

1. Evaluation of DNA ploidy combined with a cytometric proliferation index of imprints from core needle biopsies in prostate cancer
2. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years
3. A method of correcting DNA ploidy measurements in tissue sections
4. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: Influence of tumor deoxyribonucleic acid ploidy
5. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy
6. Association between in vivo iododeoxyuridine labeling, MIB-1 expression, malignancy grade and clinical stage in human prostate cancer
7. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting
8. Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade?
9. Detection of organconfined prostate cancer is increased through prostate-specific antigen-based screening
10. Cell proliferation in prostate cancer patients with lymph node metastasis: A marker for progression
11. Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer
12. Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer
13. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
14. Prognostic significance of DNA ploidy in carcinoma of prostate
15. Identification and therapy of stage B prostate carcinoma
16. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
17. National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening
18. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison
19. Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy
20. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
21. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma
22. Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma
23. Influence of noncancerous prostatic tissue volume on prostate-specific antigen
24. Elevation of prostate-specific markers after cardiopulmonary resuscitation
25. Prostate specific antigen detected prostate cancer (clinical stage T1c): An interim analysis
26. Pathological stage C (pT3) prostate cancer treated by radical prostatectomy: Clinical implications of DNA ploidy analysis
27. The prognostic value of DNA ploidy combined with histologic substaging for incidental carcinoma of the prostate gland
28. Radical prostatectomy for stage B2 prostatic cancer
29. Stage B prostate adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis
30. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer
31. DNA-ploidy, G2M-fractions and prognosis of stages B and C prostate carcinoma
32. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels
33. Biological variation of prostate specific antigen levels in serum: An evaluation of day-today physiological fluctuations in a well-defined cohort of 24 patients
34. Correlation of histologic inflammation in needle biopsy specimens with serum prostatespecific antigen levels in men with negative biopsy for prostate cancer
35. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: A multi-institutional update
36. Transrectal fine needle aspiration biopsy of the prostate combining cytomorphologic, DNA ploidy status and cell cycle distribution studies
37. The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation
38. Clinical and pathologic characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer
39. Enhanced expression of prostate-specific antigen in the transition zone of the prostate: A characterization following prostatectomy for benign hyperplasia
40. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota
41. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer
42. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer
43. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas
44. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: Correlation with total serum PSA and PSA density
45. Digital image analysis
46. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy
47. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion. Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: A report of 454 cases
48. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes
49. Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors
50. Pathologic parameters and flow cytometric ploidy analysis in predicting recurrence in carcinoma of the prostate
51. Ability of sextant biopsies to predict radical prostatectomy stage
52. Value of nuclear DNA ploidy patterns in patients with prostate cancer after radical prostatectomy
53. Postejaculation serum prostate-specific antigen level